

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
19.05.2004 Bulletin 2004/21

(51) Int Cl.⁷: C07C 237/26, A61K 31/65

(21) Application number: 94104690.6

(22) Date of filing: 24.03.1994

(54) 9-[(Substituted glycyI)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines

9-(Substituirtes Glycyl)amido-6-(substituirt)-5-hydroxy-6-deoxytetracycline

9-(Glycyle substitué)amido-6-(substitué)-5-hydroxy-6-déoxytétracyclines

<div>(84) Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE</div>	<ul style="list-style-type: none">• Buckwalter, Brian Lee Yardley, Pennsylvania 19067 (US)• Barden, Timothy Claude Holland, Pennsylvania 18966 (US)								
<div>(30) Priority: 02.04.1993 US 42302</div>									
<div>(43) Date of publication of application: 05.10.1994 Bulletin 1994/40</div>	<div>(74) Representative: Wileman, David Francis, Dr. c/o Wyeth Laboratories Huntercombe Lane South Taplow Maidenhead Berkshire SL6 OPH (GB)</div>								
<div>(60) Divisional application: 04005673.1</div>	<div>(56) References cited:</div> <table><tbody><tr><td>EP-A- 0 582 788</td><td>WO-A-93/08806</td></tr><tr><td>US-A- 3 219 671</td><td>US-A- 3 338 963</td></tr><tr><td>US-A- 3 341 585</td><td>US-A- 3 341 586</td></tr><tr><td>US-A- 3 518 306</td><td>US-A- 3 579 579</td></tr></tbody></table>	EP-A- 0 582 788	WO-A-93/08806	US-A- 3 219 671	US-A- 3 338 963	US-A- 3 341 585	US-A- 3 341 586	US-A- 3 518 306	US-A- 3 579 579
EP-A- 0 582 788	WO-A-93/08806								
US-A- 3 219 671	US-A- 3 338 963								
US-A- 3 341 585	US-A- 3 341 586								
US-A- 3 518 306	US-A- 3 579 579								
<div>(73) Proprietor: Wyeth Holdings Corporation Madison, NJ 07940 (US)</div>									
<div>(72) Inventors:<ul style="list-style-type: none">• Lee, Ving Jick Monsey, New York 10952 (US)</div>	<ul style="list-style-type: none">• "The Merck Index", 11th edition, 1989, Merck and Co. Inc., Rahway, N.J., USA, * page 541, no. 3429 *								

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

BACKGROUND OF THE INVENTION


1. Field of the Invention

[0001] The invention relates to novel [4S-(4 α ,4 α , 5 α ,5 α ,6 α ,12 α)]-4-(dimethylamino)-6-(substituted)-9-[[substituted amino]substituted]amino]-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamides herein after called 9-[(substituted glycy]amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibiotic agents.

[0002] The invention also relates to novel 9-[(haloacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline and novel 9-[(protected aminoacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.

SUMMARY OF THE INVENTION

[0003] This invention is concerned with novel 9-[(substituted glycy]amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines, represented by formula I, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compounds of formula I which have antibacterial activity against tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.



[0004] In formula I,

R is selected from α -CH₃;

R¹ is selected from hydrogen; straight or branched (C₁-C₄)alkyl group selected from methyl, ethyl, propyl and butyl; straight or branched (C₁-C₄)alkyl group optionally substituted with amino; (heterocyclo)methyl group said heterocycle selected from imidazolyl and 3-indolyl; (C₅-C₆)cycloalkylmethyl group selected from (cyclopentyl)methyl and (cyclohexyl) methyl; (C₂-C₄)carboxamidoalkyl group selected from carboxamidomethyl and carboxamidoethyl;


R² is selected from hydrogen and (C₁-C₂)alkyl selected from methyl and ethyl;

W is selected from amino; (C₁-C₈) straight or branched alkyl monosubstituted amino group substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, n-hexyl and n-octyl; (C₃-C₆)cycloalkyl monosubstituted amino group substitution selected from cyclopropyl, cyclopentyl and cyclohexyl; [(C₄-C₅)cycloalkyl] (C₁-C₂) alkyl monosubstituted amino group substitution selected from (cyclopropyl)methyl and (cyclopropyl)ethyl; (C₃-C₄)alkenyl monosubstituted amino group substitution selected from allyl and 3-butenyl; (C₇-C₁₀)aralkylamino group selected from benzyl, 2-phenylethyl and 1-phenylethyl; straight or branched symmetrical disubstituted (C₂-C₄)alkylamino group substitution selected from dimethyl and diethyl; straight or branched unsymmetrical disubstituted (C₃)alkylamino group substitution selected from methyl(ethyl); (C₂-C₅)azacycloalkyl group selected from pyrrolidinyl and piperidinyl; 1-azaoxacycloalkyl group selected from morpholinyl; substituted 1-azaoxacycloalkyl group selected from 2-(C₁-C₃)alkylmorpholinyl; [1,n]-diazacycloalkyl and substituted [1,n]-diazacycloalkyl group selected from piperazinyl, 2-(C₁-C₃)

alkylpiperazinyl, 4-(C₁-C₃)alkylpiperazinyl, and 2,5-diaza-5-methylbicyclo[2.2.1]hept-2-yl and the diastereomers and enantiomers of said [1,n]-diazacycloalkyl and substituted [1,n]-diazacycloalkyl group; 1-azathiacycloalkyl and substituted 1-azathiacycloalkyl group selected from thiomorpholinyl and 2-(C₁-C₃)alkylthiomorpholinyl; N-azolyl group selected from 1-imidazolyl; (heterocycle)methylamino group selected from 2- or 3-thienylmethylamino and 2-, 3- or 4-pyridylmethylamino; (C₁-C₄)alkoxycarbonylamino group substitution selected from methoxycarbonylamino, ethoxycarbonylamino, and 1,1-dimethylethoxycarbonylamino; or R¹ and W taken together are -CH₂CH₂CH₂NH-; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

[0005] It will be appreciated that when R¹ does not equal R² the stereochemistry of the asymmetric carbon (i.e. the carbon bearing the W substituent) may be either the racemate (DL) or the individual enantiomers (L or D).

[0006] Also included in the present invention are compounds useful as intermediates for producing the above compounds of formula I. Such intermediate include those having the formula II:



wherein:

Y is selected from (CH₂)_nX, n = 0-5, X is halogen selected from bromine, chlorine, fluorine and iodine; alternatively, X is a protected amino selected from trifluoroacetyl amino, (C₁-C₄)alkoxycarbonylamino selected from t-butoxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino, allyloxycarbonylamino and 1,1,1-trichloroethoxycarbonylamino, (C₇-C₁₄)arylalkoxycarbonylamino selected from benzyloxycarbonylamino, naphthylmethoxycarbonylamino, 9-fluorenylmethoxycarbonylamino, p-methoxybenzyloxycarbonylamino, and p-nitrobenzyloxycarbonylamino, (C₇-C₂₃)arylalkylamino selected from benzylamine, p-methoxybenzylamine, p-nitrobenzylamine, tritylamine and 4-methoxytritylamine;

and R, R¹ and R² are as defined above.

[0007] It will be appreciated that when R¹ does not equal R² the stereochemistry of the asymmetric carbon (i.e. the carbon bearing the W substituent) may be either the racemate (DL) or the individual enantiomers (L or D); and the pharmacologically acceptable organic and inorganic salts and metal complexes.


[0008] Particularly preferred compounds are compounds according to the above formula II wherein:

Y is selected from (CH₂)_nX, n = 0-5, X is halogen selected from bromine, chlorine, fluorine and iodine; alternatively, X is a protected amino selected from trifluoroacetyl amino, (C₃-C₄)alkoxycarbonylamino selected from t-butoxycarbonylamino, allyloxycarbonylamino and 1,1,1-trichloroethoxycarbonylamino, (C₇-C₁₄)arylalkoxycarbonylamino selected from benzyloxycarbonylamino, and 9-fluorenylmethoxycarbonylamino, (C₇-C₂₃)arylalkylamino selected from benzylamine, and tritylamine;


[0009] The invention also provides methods of producing the compounds of the invention, compositions comprising the compounds and their use as a medicament or in the preparation of a medicament for the treatment of bacterial infections in warm blooded animals.

[0010] Suitable salts of the compounds of the invention include inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric and sulfate salts and organic salts such as acetate, benzoate, citrate, cysteine, fumarate and other amino acid salts.

[0011] The novel compounds of the present invention may be readily prepared in accordance with the following schemes.


Scheme I

1 mineral acid
salt




3 mineral acid
salt

[0012] The 9-[(substituted glycyloxy)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines, or mineral acid salts, can be made by the procedure described in scheme I. In accordance with scheme I, 9-amino-6-(substituted)-5-hydroxy-6-deoxytetracycline or its mineral acid salt, 1, is dissolved in a mixture of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidone and acetonitrile or equivalent solvents. Sodium carbonate is added and the mixture is stirred for 5 minutes. An acid chloride, acid anhydride or suitably activated acylation reagent of the formula:




wherein X=suitable leaving group and R¹, R², and W have been described hereinabove, is added and the reaction is stirred at room temperature for from 0.5-2 hours to give the corresponding 9-[(substituted glycerylamido)-6-(substituted)-5-hydroxy-6-deoxytetracycline, or its mineral acid salt 3.

Scheme II

[0013] The second method for producing 9-[(substituted glycol)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines or its mineral acid salt **3**, is shown in scheme II. This method uses common intermediates which are easily prepared by reacting commercially available haloacyl halides, anhydrides or suitably activated haloacylating agents


of the formula:



wherein Y, R¹ and R² are as defined hereinabove and Q is halogen selected from bromine, chlorine, iodine, fluorine or suitable leaving group; with 9-amino-6-(substituted)-5-hydroxy-6-deoxytetracyclines, or its mineral acid salt 1, to give straight or branched 9-[(haloacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines or its mineral acid salt, 2, in almost quantitative yield. The above intermediates, straight or branched 9-[(haloacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines or its mineral acid salt 2, react with a wide variety of nucleophiles, especially amines, having the formula WH, wherein W is as defined hereinabove to give the new 9-[(substituted glycy)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines or mineral acid salt 3 of the present invention.

[0014] In accordance with Scheme II, 9-amino-6-(substituted)-5-hydroxy-6-deoxytetracycline or its mineral acid salt, 1, is mixed with

- a) a polar-aprotic or protic (low temp.) solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone, herein after called DMPU, hexamethylphosphoramide herein after called HMPA, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,2-dimethoxyethane, water or equivalent thereof;
- b) an inert solvent such as acetonitrile, methylene chloride, tetrahydrofuran chloroform, carbon tetrachloride, 1,2-dichloroethane, tetrachloroethane, diethyl ether, t-butyl methyl ether, isopropyl ether or equivalent thereof;
- c) a base such as sodium carbonate, sodium bicarbonate, sodium acetate, potassium carbonate, potassium bicarbonate, triethylamine, cesium carbonate, lithium carbonate or bicarbonate equivalents; and
- d) a straight or branched haloacyl halide, anhydride or suitably activated haloacylating agent of the formula:



wherein Y, R¹, R² and Q are as defined hereinabove such as bromoacetyl bromide, (bromoacetic anhydride, chloroacetyl chloride (chloroacetic anhydride) or 2-bromopropionyl bromide or equivalent thereof; the halo, Y, and halide, Q, in the haloacyl halide can be the same or different halogen and is selected from bromine, chlorine, iodine and fluorine; Y is (CH₂)_nX, n= 0-5, X is halogen;


- e) for 0.5 to 5 hours at room temperature to the reflux temperature of the reaction; to form the corresponding 9-[(haloacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline, 2, or its mineral acid salt.

[0015] The intermediate, 9-[(haloacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline or mineral acid salt 2, is treated, under an inert atmosphere of helium, argon or nitrogen, with

- a) a nucleophile WH such as an amine or substituted amine or equivalent for example methylamine, dimethylamine, ethylamine, n-butylamine, propylamine or n-hexylamine;
- b) a polar-aprotic or protic solvent such as DMPU, HMPA, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,2-dimethoxyethane, water or equivalent;
- c) for from 0.5 - 2 hours at room temperature or under reflux temperature to produce the desired 9-[(substituted glycy)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline, 3, or its mineral acid salt.

[0016] Alternatively, the intermediate, 9-[(protected aminoacyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline (Y=protected amino group), is treated under an inert atmosphere of helium, argon or nitrogen with an appropriate nitrogen deprotection reagent using methods known to those skilled in the art [(a) Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 1989; (b) Theodora Greene, Protecting Groups in Organic Synthesis, Academic Press, 1991]. It is well known to one skilled in the art that the appropriate nitrogen protection and deprotection scheme is chosen based on chemical and physical stability.

Scheme III



[0017] In accordance with Scheme III, compounds of formula 3 are N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D)alanine, (L or D)lysine or their substituted congeners; or a secondary amine such as morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adduct, 4.

[0018] The 9-[(substituted glycol)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowability, hygroscopicity and solubility. Pref-

erably, the 9-[(substituted glycy)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines are obtained as inorganic salt such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salt such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate. Depending on the stoichiometry of the acids used, the salt formation occurs with the C(4)-dimethylamino group (1 equivalent of acid) or with both the C(4)-dimethylamino group and the W group (2 equivalents of acid). The salts are preferred for oral and parenteral administration.

[0019] Some of the compounds of the hereinbefore described Schemes have centers of asymmetry at the carbon bearing the W substituent. The compounds may, therefore, exist in at least two (2) stereoisomeric forms. The present invention encompasses the racemic mixture of stereo isomers as well as all stereoisomers of the compounds whether free from other stereoisomers or admixed with stereoisomers in any proportion of enantiomers. The absolute configuration of any compound may be determined by conventional X-ray crystallography.

[0020] The stereochemistry centers on the tetracycline unit (i.e. C-4, C-4a, C-5, C-5a, C-6 and C-12a) remain intact throughout the reaction sequences.

BIOLOGICAL ACTIVITY

Method for in Vitro Antibacterial Evaluation

(Table 1)

[0021] The minimum inhibitory concentration (MIC), the lowest concentration of the antibiotic which inhibits growth to the test organism, is determined by the agar dilution method using Muller-Hinton II agar (Baltimore Biological Laboratories). An inoculum density of $1-5 \times 10^5$ CFU/ml and a range of antibiotic concentrations (32-0.004 pg/ml) is used. The plates are incubated for 18 hours at 35°C in a forced air incubator. The test organisms comprise strains that are sensitive to tetracycline and genetically defined strains that are resistant to tetracycline, due to inability to bind to bacterial ribosomes (tetM) or by a tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell.

Testing Results

[0022] The claimed compounds exhibited good in vitro activity against a spectrum of doxycycline-sensitive and doxycycline-resistant Gram-positive and Gram-negative bacteria (Table 1). Notably, compounds A-D, compared to doxycycline, exhibited excellent in vitro activity against strains containing the two major resistance determinants: efflux, as represented by tetB and tetD (*E. coli* UBMS 88-1, *E. coli* MC4100 and *E. coli* J3272) and ribosomal protection, as represented by *S. aureus* UBMS 90-1 and UBMS 90-2 and *E. coli* UBMS 89-1 and 90-4. These compounds showed improved activity against *Enterococcus* and comparable activity to doxycycline against sensitive strains. Compounds E-F exhibited similar activity against doxycycline-resistant, both efflux and ribosomal protection mechanisms, and doxycycline-susceptible strains. Compounds G-H showed similar activity against doxycycline susceptible *S. aureus* strains and doxycycline-resistant (both efflux and ribosomal resistant) strains. Compounds I-J had similar activity against doxycycline-sensitive strains and strains resistant to doxycycline due to ribosomal protection, but were less effective against strains carrying the efflux (tetK) resistance mechanism.

[0023] As can be seen from Table 1, compounds of the invention can be used to prevent or control important mammalian and veterinary diseases such as diarrhea, urinary tract infections, infections of skin and skin structure, ear, nose and throat infections, wound infections, mastitis and the like.

[0024] Thus, the improved efficacy of 9-[(N,N-dimethylglycy)amido]-6-(substituted)-5-hydroxy-6-deoxytetracycline is demonstrated by the in vitro activity against isogenic strains into which the resistance determinants, such as tetM, are cloned (Table 1).

LEGEND FOR COMPOUNDS

[0025]

Compound	Name
Doxycycline	[4S-(4alpha,12alpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12, 12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
A	[4S-(4alpha,12alpha)]-4-(Dimethylamino)-9-[[dimethylamino)acetyl]amino]-1,4,4a, 5,5a, 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

(continued)

Compound	Name
B	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-leucyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
C	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-phenylalanyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
D	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(D-phenylalanyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
E	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[beta-(cyclohexyl)alanyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
F	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-prolyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
G	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(N,N-dimethylphenylalanyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
H	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-N-methylleucyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
I	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-tryptophanyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
J	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-tyrosyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
K	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-glutaminy]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
L	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(glycyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
M	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(bromoacetyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
(comparative example)	
N	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[(L-lysyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

Table 1. Antimicrobial Activity of 9-(α -Aminoacyl)-6-(substituted)-5-hydroxy-6-deoxytetracyclines

ORGANISM	Doxycycline	A	B	C	D	E	F	G
<i>E. coli</i> UBMS 88-1 (tetB)	32.00	1.00	2.00	4.00	4.00	8.00	4.00	32.00
<i>E. coli</i> MC4100 (tet-sensitive)	0.25	0.25	0.50	0.50	1.00	2.00	1.00	8.00
<i>E. coli</i> PRP1 (tetA)	8.00	4.00	16.00	16.00	8.00	8.00	16.00	16.00
<i>E. coli</i> MC4100 (TN10WT)	>32.00	1.00	2.00	4.00	4.00	4.00	4.00	>32.00
<i>E. coli</i> J3272 (tetC)	8.00	8.00	4.00	8.00	4.00	8.00	8.00	32.00
<i>E. coli</i> UBMS 89-1 (tetM)	16.00	0.50	1.00	2.00	4.00	2.00	2.00	8.00
<i>E. coli</i> UBMS 89-2 (tet-sensitive)	2.00	0.50	1.00	4.00	4.00	8.00	2.00	32.00
<i>E. coli</i> J2175 (par J2445)	2.00	0.50	2.00	4.00	4.00	4.00	2.00	32.00
<i>E. coli</i> J2445 (IMP mut)	0.25	0.12	0.50	0.50	0.50	1.00	1.00	2.00
<i>E. coli</i> UBMS 90-4 (tetM)	32.00	0.25	1.00	2.00	2.00	4.00	2.00	16.00
<i>E. coli</i> UBMS 90-5 K-12	1.00	0.50	1.00	4.00	4.00	4.00	2.00	32.00
<i>E. coli</i> #311 MP (Mino-sensitive)	1.00	0.50	1.00	2.00	4.00	4.00	2.00	16.00
<i>E. coli</i> ATCC 25922	1.00	0.50	1.00	2.00	4.00	4.00	2.00	16.00
<i>E. coli</i> J3272 (tetD)	32.00	0.25	1.00	1.00	1.00	2.00	1.00	16.00
<i>Serr. marc.</i> FPOR 87-33	16.00	8.00	32.00	>32.00	>32.00	>32.00	16.00	>32.00
<i>X. maltophilia</i> NEMC 87-2	1.00	4.00	16.00	32.00	>32.00	>32.00	32.00	32.00
<i>Ps. aeruginosa</i> ATCC 2785	32.00	16.00	32.00	>32.00	>32.00	>32.00	>32.00	>32.00
<i>S. aureus</i> NEMC 89-4 (MRSA)	0.12	0.25	1.00	0.50	2.00	2.00	2.00	2.00
<i>S. aureus</i> UBMS 88-4 (par 88-5, tetM)	0.06	0.25	1.00	0.50	1.00	2.00	2.00	1.00
<i>S. aureus</i> UBMS 88-5 (tetM)	8.00	0.50	1.00	1.00	4.00	4.00	4.00	2.00
<i>S. aureus</i> UBMS 88-7 (tetK)	4.00	4.00	2.00	4.00	16.00	2.00	4.00	2.00
<i>S. aureus</i> UBMS 90-1 (tetM)	8.00	0.50	1.00	2.00	8.00	8.00	4.00	2.00
<i>S. aureus</i> UBMS 90-3	0.06	0.12	0.50	0.50	1.00	0.50	1.00	1.00
<i>S. aureus</i> UBMS 90-2 (tetM)	8.00	0.50	0.50	0.50	2.00	2.00	2.00	2.00
<i>S. aureus</i> IVES 2943 (tet-resist)	16.00	8.00	4.00	16.00	32.00	4.00	32.00	2.00
<i>S. aureus</i> ROSE MP (tet-resist)	8.00	8.00	8.00	32.00	>32.00	8.00	>32.00	8.00
<i>S. aureus</i> SMITH MP (mino-sens)	0.12	0.25	0.50	0.50	0.50	1.00	2.00	4.00
<i>S. aureus</i> IVES 1983 MP	16.00	8.00	2.00	8.00	32.00	8.00	32.00	2.00
<i>S. aureus</i> ATCC 29213	0.06	0.25	1.00	1.00	1.00	2.00	2.00	2.00
<i>S. hemolyticus</i> AVAH 88-3	0.25	0.50	2.00	8.00	8.00	8.00	4.00	4.00
<i>Enterococcus</i> 12201 (vanc-resist.)	8.00	0.50	0.50	1.00	4.00	2.00	4.00	1.00
<i>E. faecalis</i> ATCC 29212	4.00	0.25	0.25	0.50	0.50	0.50	2.00	1.00

Table 1 (cont.). Antimicrobial Activity of 9-(α -Aminoacyl)-6-(substituted)-5-hydroxy-6-deoxytetracyclines

ORGANISM	Doxycycline	H	I	J	K	L	M	N
<i>E. coli</i> UBMS 88-1 (tetB)	32.00	8.00	8.00	16.00	>32.00	16.00	>32.00	>32.00
<i>E. coli</i> MC4100 (tet-sensitive)	0.25	1.00	2.00	2.00	4.00	4.00	>32.00	>32.00
<i>E. coli</i> PRP1 (tetA)	8.00	16.00	16.00	32.00	>32.00	>32.00	>32.00	>32.00
<i>E. coli</i> MC4100 (TN10WT)	>32.00	4.00	8.00	16.00	>32.00	32.00	>32.00	>32.00
<i>E. coli</i> J3272 (tetC)	8.00	8.00	8.00	16.00	>32.00	>32.00	>32.00	>32.00
<i>E. coli</i> UBMS 89-1 (tetM)	16.00	4.00	8.00	16.00	>32.00	8.00	>32.00	>32.00
<i>E. coli</i> UBMS 89-2 (tet-sensitive)	2.00	8.00	8.00	16.00	16.00	8.00	>32.00	>32.00
<i>E. coli</i> J2175 (par J2445)	2.00	4.00	8.00	16.00	16.00	8.00	>32.00	>32.00
<i>E. coli</i> J2445 (IMP mut)	0.25	1.00	1.00	1.00	4.00	4.00	>32.00	>32.00
<i>E. coli</i> UBMS 90-4 (tetM)	32.00	4.00	4.00	8.00	>32.00	8.00	>32.00	>32.00
<i>E. coli</i> UBMS 90-5 K-12	1.00	4.00	8.00	8.00	16.00	8.00	>32.00	>32.00
<i>E. coli</i> #311 MP (Mino-sensitive)	1.00	4.00	8.00	16.00	16.00	8.00	>32.00	>32.00
<i>E. coli</i> ATCC 25922	1.00	4.00	8.00	16.00	16.00	8.00	>32.00	>32.00
<i>E. coli</i> J3272 (tetD)	32.00	2.00	4.00	8.00	>32.00	8.00	>32.00	>32.00
<i>Serr. marc.</i> FPOR 87-33	16.00	>32.00	>32.00	>32.00	>32.00	32.00	>32.00	>32.00
<i>X. maltophilia</i> NEMC 87-2	1.00	>32.00	>32.00	>32.00	16.00	>32.00	>32.00	>32.00
<i>Ps. aeruginosa</i> ATCC 2785	32.00	>32.00	>32.00	>32.00	>32.00	>32.00	>32.00	>32.00
<i>S. aureus</i> NEMC 89-4 (MRSA)	0.12	2.00	4.00	2.00	2.00	8.00	16.00	>32.00
<i>S. aureus</i> UBMS 88-4 (par 88-5, tetM)	0.06	2.00	4.00	2.00	2.00	8.00	16.00	>32.00
<i>S. aureus</i> UBMS 88-5 (tetM)	8.00	2.00	4.00	2.00	>32.00	16.00	>32.00	>32.00
<i>S. aureus</i> UBMS 88-7 (tetK)	4.00	2.00	16.00	32.00	32.00	>32.00	16.00	16.00
<i>S. aureus</i> UBMS 90-1 (tetM)	8.00	2.00	4.00	4.00	>32.00	16.00	>32.00	>32.00
<i>S. aureus</i> UBMS 90-3	0.06	1.00	2.00	0.50	1.00	4.00	8.00	>32.00
<i>S. aureus</i> UBMS 90-2 (tetM)	8.00	1.00	4.00	1.00	>32.00	8.00	>32.00	>32.00
<i>S. aureus</i> IVES 2943 (tet-resist)	16.00	2.00	32.00	>32.00	>32.00	>32.00	>32.00	>32.00
<i>S. aureus</i> ROSE MP (tet-resist)	8.00	16.00	32.00	>32.00	>32.00	>32.00	>32.00	>32.00
<i>S. aureus</i> SMITH MP (mimo-sens)	0.12	2.00	1.00	1.00	4.00	8.00	8.00	>32.00
<i>S. aureus</i> IVES 1983 MP	16.00	4.00	16.00	>32.00	>32.00	>32.00	>32.00	>32.00
<i>S. aureus</i> ATCC 29213	0.06	4.00	4.00	2.00	2.00	8.00	16.00	>32.00
<i>S. hemolyticus</i> AVAH 88-3	0.25	16.00	16.00	16.00	4.00	16.00	>32.00	>32.00
<i>Enterococcus</i> 12201 (vanc-resist.)	8.00	2.00	2.00	1.00	>32.00	16.00	>32.00	>32.00
<i>E. faecalis</i> ATCC 29212	4.00	1.00	1.00	0.50	>32.00	4.00	>32.00	>32.00

[0026] When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms

as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing for example, from about 20 to 50% ethanol and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

[0027] An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0028] These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

[0029] The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

[0030] These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0031] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserve against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

[0032] The invention will be more fully described in conjunction with the following specific examples which are not be construed as limiting the scope of the invention.

Example 1

[4S-(4 α ,12 α)]-9-[(Bromoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0033] A stirred mixture of 0.030 g of 9-amino-5-hydroxy-6-deoxytetracycline, 0.10 g of sodium bicarbonate and 1 ml of N-methylpyrrolidinone at ambient temperature, is treated with 0.010 ml of bromoacetyl bromide. After 20 minutes, the suspension is filtered into stirred diethyl ether and the crude product is filtered. The crude product is purified by preparative HPLC to give 0.015 g of the desired product as a yellow glass.

MS(FAB): m/z 579 (M+H) and 581 (M+H).

¹H NMR (CD₃OH): δ 8.20(d,1H,J=8.3Hz,H-8); 6.90(d,1H, J=8.3Hz,H-7); 4.37(bs,1H,H-4); 4.08(s,2H,CH₂Br); 3.52(dd, 1H,J=8.25;11.40Hz,H-5); 2.92(bs,6H,NMe₂); 2.70-2.90(m,2H,H-4a and H-6); 2.51(dd,J=8.25;12.36Hz, H-5a) and 1.50 (d,3H,J=6.7Hz,C-CH₃).

Example 2

[4S-(4 α ,12 α)]-9-[(Bromoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide

[0034] To a room temperature solution of 1.75 g of 9-amino-5-hydroxy-6-deoxytetracycline monosulfate, 20 ml of

1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone, hereinafter called DMPU, and 4 ml of acetonitrile is added 0.60 g of sodium carbonate. The mixture is stirred for 5 minutes followed by addition of 1.100 g of bromoacetyl bromide. The reaction is stirred one hour, filtered, and the filtrate added dropwise to a mixture of 50 ml of isopropanol and 500 ml of diethyl ether. The resulting yellow solid is collected, washed first with the mixed solvent (isopropanol and diethyl ether),

followed by diethyl ether and dried to give 1.40 g of product.

MS(FAB): m/z 579 (M+H) and 581 (M+H).

Example 3

[4S-(4alpha,12aalpha)]-9-[(Chloroacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride

[0035] To a room temperature solution of 0.05 g of 9-amino-5-hydroxy-6-deoxytetracycline hydrochloride, 1.5 ml of DMPU and 0.5 ml of acetonitrile is added 0.023 g of chloroacetyl chloride. The mixture is stirred for 30 minutes, then poured into a mixture of 0.5 ml of methyl alcohol, 2 ml of isopropyl alcohol and 20 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.040 g of the desired product.

MS(FAB): m/z 535 (M+H) and 537(M+H).

Example 4

[4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide

[0036] The title compound is prepared by the procedure of Example 2, using 2.0 g of 9-amino-5-hydroxy-6-deoxytetracycline hydrochloride, 0.7 g of sodium carbonate, 20 ml of DMPU, 8 ml of acetonitrile and 1.73 g of 2-bromopropionyl bromide. The reaction is stirred for 1 hour to give 1.55 g of the desired product. This reaction works equally well without sodium carbonate.

MS(FAB): m/z 593 (M+H) and 595 (M+H).

Example 5

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-1-piperidineacetamide

[0037] A solution of 0.108 g of product from Example 1, 1 ml of piperidine and 2 ml of N-methylpyrrolidone, under argon, is stirred at room temperature for 30 minutes. The reaction is concentrated *in vacuo* and the residue diluted with 1 ml of methanol. The solution is added dropwise to 100 ml of diethyl ether and the precipitate collected, washed with diethyl ether and dried to give a yellow product. The yellow solid is purified by preparative HPLC to give 0.045 g of the desired product as a yellow glass.

MS(FAB): m/z 585 (M+H).

¹H NMR (CD₃OH): δ 8.23(d,1H,J=8.3Hz,H-8); 6.95(d,1H, J=8.3Hz,H-7); 4.37(bs,1H,H-4); 4.13(s,2H,COCH₂N); 3.52(dd,1H,J=8.25;11.40Hz,H-5); 2.92(bs,6H,NMe₂); 2.70-2.90(m,2H,H-4a and H-6); 2.51(dd,J=8.25;12.36Hz, H-5a); 2.3-2.55(m,4H); 1.70-1.99(m,6H) and 1.51(d,3H, J=6.7Hz,C-CH₃).

Example 6

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-1-piperidineacetamide dihydrochloride

[0038] A solution of 0.215 g of product from Example 1, 4 ml of piperidine and 4 ml of N-methylpyrrolidone, under argon, is stirred at room temperature for 30 minutes. The reaction is concentrated *in vacuo* and the residue diluted with 2 ml of methanol and added dropwise to 150 ml of diethyl ether. 2M hydrochloric acid in diethyl ether is added to give a yellow solid. The resulting solid is collected, washed with diethyl ether and dried to give 0.20 g of product.

MS(FAB): m/z 585 (M+H).

[0039] Substantially following the methods described in detail hereinabove, in Examples 5 or 6, the compounds of this invention listed below in Examples 7-22 are prepared.

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
7	[4S-(4alpha,12aalpha)]-4-(dimethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	1	Methylamine (40% in water)	2.5 hrs.	531 (M+H)
8	[4S-(4alpha,12aalpha)]-4-(Dimethyl-amino)-9-[[[(ethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	1	Ethylamine (70% in water)	2.0 hr.	545 (M+H)
9	[7S-(7alpha,10aalpha)]-N-[9-(Amino-carbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-penta-hydroxy-5-methyl-10,12-dioxo-2-naphtha-cenyl]-1-pyrrolidineacetamide	1	Pyrrolidine	2.0 hr.	571 (M+H)
10	[7S-(7alpha,10aalpha)]-N-[9-(Aminocar-bonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-methyl-1-piperidineacetamide	2	4-Methyl-piperidine	1.0 hr.	599 (M+H)
11	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(propylamino)acetyl]amino]-2-naphtha-cenecarboxamide dihydrochloride	2	Propylamine	1 hr.	559 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
12	[4S-(4alpha,12aalpha)]-9-[[[(Butylamino)acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide]	2	n-Butylamine	2 hr.	573 (M+H)
13	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide dihydrochloride]	4	Dimethylamine	2 hr.	559 (M+H)
14	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide monohydrochloride]	1	Amylamine	2 hr.	587 (M+H)
15	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)acetyl]-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide]	1	Dimethylamine	2 hr.	545 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
16	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(phenylmethyl)-amino]acetyl]amino]-2-naphthacene-carboxamide dihydrochloride	1	Benzylamine	2 hr.	607 (M+H)
17	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-thienylmethyl)amino]acetyl]amino]-2-naphthacene-carboxamide dihydrochloride	1	2-Thiophene-methylamine	1 1/2 hr.	613 (M+H)
18	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacene-carboxamide dihydrochloride	3	Isobutylamine	2 hr.	573 (M+H)
19	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-pyridinylmethyl)amino]acetyl]amino]-2-naphthacene-carboxamide dihydrochloride	3	2-(Aminomethyl)pyridine	1 1/2 hr.	608 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
20	[4S-(4alpha,12aalpha)]-9-[[[(Diethylamino)acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide]	1	Diethylamine	1 1/2 hr.	573 (M+H)
21	[7S-(7alpha,10aalpha)]-N-9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidinecarboxamide	3	2-Methylpyrrolidine	1 hr.	583 (M+H)
22	[4S-(4alpha,12aalpha)]-9-[[[(Cyclopropylmethyl)amino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	3	(Aminomethyl)cyclopropane	1 hr.	571 (M+H)
23	[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(t-butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide]	1	t-Butylamine	2 hr.	573 (M+H)

Example 24General Procedure for the Preparation of Mannich Bases.

- 5 **[0040]** A mixture of 0.5 mm of product from Example 23 (free base), 3 ml of t-butyl alcohol, 0.55 mm of 37% formaldehyde, and 0.55 mm of pyrrolidine, morpholine or piperidine is stirred at room temperature for 30 minutes followed by heating at 100°C for 15 minutes. The reaction mixture is cooled to room temperature and triturated with diethyl ether and hexane. The solid is collected, washed with diethyl ether and hexane, and dried to give the desired product. In this manner the following compound is made:
- 10 **[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[t-butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide**
- [0041]** Substantially following the method described in Example 5, the compounds of this invention listed below in Examples 25-48 are prepared using the product from Examples 1, 2 or 3.

15

20

25

30

35

40

45

50

55

Example 25

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[methoxyamino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 26

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(phenylmethoxy) amino]acetyl]amino]-2-naphthacenecarboxamide

Example 27

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-ethyl-1H-pyrazole-1-acetamide

Example 28

[4S-(4alpha,12aalpha)]-9-[[Cyclobutylmethylamino]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

Example 29

[4S-(4alpha,12aalpha)]-9-[[2-Butenylamino]acetyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacenecarboxamide

Example 30

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[hydroxyamino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 31

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[methyl(phenylmethyl)-amino]acetyl]amino]-2-naphthacenecarboxamide

Example 32

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-acetamide

Example 33

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-methyl-4-morpholineacetamide

Example 34

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-2-azabicyclo[2.2.1]heptane-2-acetamide

Example 35

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-6-methyl-2-azabicyclo[2.2.2]octane-2-acetamide

Example 36

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,

11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-4-methyl-1-piperazinecarboxamide

Example 37

- 5 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-4-hydroxy-1-piperazineacetamide

Example 38

- 10 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-methyl-1-piperazinecarboxamide

Example 39

- 15 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-cyclopropyltetrahydro-4H-thiazine-4-acetamide

Example 40

- 20 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-ethyl-1H-pyrrole-1-acetamide

Example 41

- 25 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(1H-imidazol-2-ylmethylamino)-acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 42

- 30 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxoethyl]alanine

Example 43

- 35 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxoethyl]carbamic acid 1,1-di methyl ester

Example 44

- 40 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(2-methylcyclopropyl)oxy]amino]-acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 45

- 45 [4S-(4alpha,12aalpha)]-9-[[[(Bicyclo[2.2.2]oct-2-yloxy)amino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

Example 46

- 50 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(3-methyl-2-butenyl)amino]-acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 47

- 55 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[4-[(2-methyl-1-oxopropyl)-amino]phenyl]amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 48

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-ethyl-1-pyrrolidineacetamide

[0042] Substantially following the method described in Example 5, the compounds of this invention listed below in Examples 49-55 are prepared using the product from Example 4.

Example 49

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[[(1-methyl-1H-imidazol-2-yl)-methyl]amino]-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

Example 50

[4S-(4alpha,12aalpha)]-9-[[2-(Dicyclopropylamino)-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

Example 51

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-10,12-dioxo-2-naphthaceny]-4-methoxy- α -methyl-1-piperazinecarboxamide

Example 52

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]tetrahydro- α ,2-dimethyl-4H-1,4-thiazine-4-acetamide

Example 53

[7S-(7alpha,10aalpha)]-2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxo-1-methylethyl]carbamic acid 2-propenyl ester

Example 54

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-4-(aminomethyl)- α -methyl-1-piperidine acetamide

Example 55

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[3-(methylsulfonyl)phenyl]-amino]-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide

[0043] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 56 is prepared.

Example 56

[4S-(4alpha,12aalpha)]-9-[[2-Bromo-2-methyl-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 57

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-methyl-2-(methylamino)-1-oxopropyl]-amino]-1,11-dioxo-2-naphthacenecarboxamide

[0044] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 56 and methylamine.

Example 58

[4S-(4 α ,12 α)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-methyl-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0045] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 56 and dimethylamine.

[0046] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 59 is prepared.

Example 59

[4S-(4 α ,12 α)]-9-[(2-Bromo-1-oxobutyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 60

[4S-(4 α ,12 α)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(3-methylcyclobutyl)oxy]amino]-1-oxobutyl]-amino]-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

[0047] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 59 and 3-methylcyclobutylamine.

Example 61

[4S-(4 α ,12 α)]-9-[[2-[(1,1-dimethylethyl)-methylamino]-1-oxobutyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0048] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 59 and N-methyl-t-butylamine.

Example 62

[7S-(7 α ,10 α)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,20a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]- α -ethyl-4-methyl-2-isoxazolidineacetamide

[0049] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 59 and 4-methyl-2-isoxazolidine.

Example 63

[7S-(7 α ,10 α)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]- α -ethyl-3-methyl-4H-1,2,4-triazole-4-acetamide

[0050] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 59 and 3-methyl-1,2,4-triazole.

[0051] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 64 is prepared.

Example 64

[4S-(4 α ,12 α)]-9-[(2-Bromo-1-oxopentyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 65

[4S-(4 α ,12 α)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-1-oxopentyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0052] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 64 and dimethylamine.

[0053] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 66 is prepared.

Example 66

[4S-(4 α ,12 α)]-9-[(2-Bromo-2-methyl-1-oxo butyl)amino]-4-dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 67

[4S-(4 α ,12 α)]-4-(Dimethylamino)-9-[[2-(ethylamino)-2-methyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0054] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 66 and ethylamine.

[0055] Substantially following the method, described in detail hereinabove in Example 2, the compound of invention Example 68 is prepared.

Example 68

[4S-(4 α ,12 α)]-9-[(2-Bromo-3-hydroxy-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 69

[4S-(4 α ,12 α)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-3-hydroxy-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0056] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 68 and dimethylamine.

Example 70

[7S-(7 α ,10 α)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]- α -(hydroxymethyl)-4-methyl-1H-imidazole-1-acetamide

[0057] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 68 and 4-methylimidazole.

[0058] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 71 is prepared.

Example 71

[4S-(4alpha,12aalpha)]-9-[(2-Bromo-3-mercapto-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,-12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 72

[4S-(4alpha,12aalpha)]-9-[(2-(Diethylamino)-3-mercapto-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0059] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 71 and diethylamine.

Example 73

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-alpha-(mercaptomethyl)-1-piperazineacetamide

[0060] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 71 and piperazine.

[0061] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 74 is prepared.

Example 74

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-3-bromo-4-oxobutanoic acid hydrobromide

Example 75

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-3-(hexylamino)-4-oxobutanoic acid

[0062] The titled compound is prepared by the procedure by Example 5. The reactants are the product from Example 74 and n-hexylamine.

Example 76

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]tetrahydro-6-(hydroxymethyl)-2H-1,2-isoxazine-2-propanoic acid

[0063] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 74 and 6-(hydroxymethyl)-1,2-isoxazine.

Example 77

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-3-[ethyl(phenylmethyl)amino]-4-oxobutanoic acid

[0064] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 74 and N-ethylbenzylamine.

[0065] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 78 is prepared.

Example 78

[7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a-11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-4-bromo-5-oxopentanoic acid hydrobromide

Example 79

[7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-4-(cyclopropylamino)-5-oxopentanoic acid

[0066] The titled compound is prepared by procedure of Example 5. The reactants are the product from Example 78 and cyclopropylamine.

[0067] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 80 is prepared.

Example 80

[4S-(4alpha,12aalpha)]-9-[(alpha-Bromophenylacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 81

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-phenylacetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0068] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 80 and dimethylamine.

[0069] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 82 is prepared.

Example 82

[4S-(4alpha,12aalpha)]-9-[[Bromo(4-hydroxyphenyl)-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 83

[4S-(4alpha,12aalpha)]-9-[[Butylamino](4-hydroxyphenyl)acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0070] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 82 and n-butylamine.

[0071] Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 84 is prepared.

Example 84

[4S-(4alpha,12aalpha)]-9-[[Bromo(4-methoxyphenyl)-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 85

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-(4-methoxyphenyl)acetyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0072] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 84 and dimethylamine.

[0073] Substantially following the method, described in detail herein above in Example 2, the compound of invention

Example 86 is prepared.

Example 86

- 5 [4S-(4alpha,12aalpha)]-9-[[Bromo[4-(trifluoromethyl)-phenyl]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,-11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 87

- 10 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(ethylmethylamino)-3-[4-(trifluoromethyl)phenyl]-acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0074] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 86 and N-ethylmethylamine.

- 15 **[0075]** Substantially following the method, described in detail herein above in Example 2, the compound of invention Example 88 is prepared.

Example 88

- 20 [4S-(4alpha,12aalpha)]-9-[[Bromo[4-(dimethylamino)-phenyl]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,-11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

Example 89

- 25 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[4-(dimethylamino)phenyl](2-propenylamino)acetyl]-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0076] The titled compound is prepared by the procedure of Example 5. The reactants are the product from Example 88 and N-allylamine.

30

Example 90

- 35 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester

[0077] To a room temperature solution of 0.175 g of N-(tert-butoxycarbonyl)glycine in 5 ml of methylene chloride is added 0.91 g of dicyclohexylcarbodiimide. The reaction mixture is stirred for 30 minutes, filtered and concentrated in vacuo. The residue is dissolved in 2 ml of N-methylpyrrolidone and added to a solution of 0.142 g of 9-amino-5-hydroxy-6-deoxytetracycline in 2 ml of N-methylpyrrolidinone. After 2 hours, the solvent is concentrated in vacuo and the residue is purified by reverse phase chromatography to give 0.160 g of the desired product.

40

MS(FAB): m/z 617 (M+H)

¹H NMR (CD₃OH): δ 8.30(d, 1H, J=8.1 Hz, H-8);

6.87(d, 1H, H-7); 4.37(bs, 1H, H-4), 4.18(s, 2H, CH₂CON-); 3.53(dd, 1H, J=8.25 and 11.40 Hz, H-5); 2.93(bs, 6H, N(CH₃)₂);

2.70-2.90(m, 2H, H-4a and H-6); 2.51(dd, 1H, J=8.25 and 12.36 Hz, H-5a);

45

1.96(s, 9H, t-butyl); 1.50(d, 3H, C(6)-CH₃).

Example 91

- 50 [4S-(4alpha,12aalpha)]-9-[(Aminoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0078] The product from Example 90 is dissolved in 4 ml of trifluoroacetic acid/anisole (9:1), stirred for 45 minutes and slowly poured into 150 ml of diethyl ether. The precipitate is collected and purified by reverse phase chromatography to give 0.10 g of the desired product as a gold glass.

55

MS(FAB): m/z 517 (M+H).

¹H NMR (CD₃OH): δ 8.24(d, 1H, J=8.2 Hz, H-8);

6.92(d, 1H, H-7); 4.35(bs, 1H, H-4); 3.91(s, 2H, CH₂CON-); 3.52(dd, 1H, J=8.24 and 11.40 Hz, H-5); 2.92(bs, 6H, N(CH₃)₂);

2.70-2.90(m, 2H, H-4a and H-6); 2.52(dd, 1H, J=8.24 and 12.36 Hz, H-5a); 1.50(d, 3H, C(6)-CH₃).

Example 92

[4S-(4 α ,12 α)]-9-[L-(N-Methyleucyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0079] The title compound is prepared by the tandem procedure of Examples 90 and 91.

N-(tert-butoxycarbonyl)-N-methyl-L-leucine is coupled with 9-amino-5-hydroxy-6-deoxytetracycline to give the protected intermediate which is then deprotected and purified to give the desired compound.

MS(FAB): m/z 587 (M+H).

¹H NMR (CD₃OH): δ 8.11(d, 1H, J=8.2 Hz, H-8);

6.97(d, 1H, H-7); 4.37(bs, 1H, H-4); 4.08(dd, 1H, CHCONH); 3.53(dd, 1H, J=8.25 and 11.40 Hz, H-5); 2.94(bs, 6H, NMe₂); 2.70-2.90(m, 2H, H-4a and H-6); 2.71(s, 3H, NCH₃); 2.51(dd, 1H, J=8.25 and 12.36 Hz, H-5a); 1.52(d, 3H, J=7.1 Hz, C(6)-CH₃); 1.5-1.6(m, 3H, CH-CH₂C); 0.90(d, 6H, Me₂CH).

Example 93

[4S-(4 α ,12 α)]-9-[(L-Glutamyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0080] The title compound is prepared by the tandem procedure of Example 90 and 91. tert-Butyl N-(tert-butoxycarbonyl)- γ -L-glutamate is coupled with 9-amino-5-hydroxy-6-deoxytetracycline to give the protected intermediate which is then deprotected and purified to give the desired compound.

MS(FAB): m/z 589 (M+H).

Example 94

[4S-(4 α ,12 α)]-9-[(L-Aspartyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0081] The title compound is prepared by the tandem procedure of Example 90 and 91. tert-Butyl N-(tert-butoxycarbonyl)- β -L-aspartate is coupled with 9-amino-5-hydroxy-6-deoxytetracycline to give the protected intermediate which is then deprotected and purified to give the desired compound.

MS(FAB): m/z 575 (M+H).

Example 95

[4S-(4 α ,12 α)]-9-[(D-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0082] To a room temperature solution of 0.40 g of N-(9-fluorenylmethoxycarbonyl)-D-phenylalanine in 20 ml of methylene chloride/tetrahydrofuran (1:1) is added 0.095 g of dicyclohexylcarbodiimide. The reaction mixture is stirred for 1 hour, filtered and concentrated in vacuo. The residue is added to a solution of 0.151 g 9-amino-5-hydroxy-6-deoxytetracycline in 3 ml of N-methylpyrrolidone and the mixture is stirred for 4 hours. One ml of piperidine is added and the mixture stirred for an additional 20 minutes. The reaction mixture is slowly poured into 150 ml of stirring diethyl ether and the resulting precipitate is collected. The light yellow powder is purified by preparative chromatography to give 0.049 g of the desired product as a dark yellow glass.

MS(FAB): m/z 607 (M+H).

¹H NMR (CD₃OH): δ 8.11(d, 1H, J=6.9 Hz, H-8); 7.31(bs, 5H, C₆H₅); 6.92(d, 1H, H-7); 4.40(t, 1H, J=8.9 Hz, CHCO); 4.37(bs, 1H, H-4); 3.53(dd, J=8.25 and 11.40 Hz, H-5); 3.15(d, 2H, J=8.9 Hz, CH₂CHO); 2.92(bs, 6H, NMe₂); 2.70-2.90(m, 2H, H-4a and H-6); 2.51(dd, 1H, J=8.25 and 12.35 Hz, H-5a); and 1.50(d, 3H, J=7.1 Hz, C(6)-CH₃).

Example 96

[4S-(4 α ,12 α)]-9-[(L-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0083] The title compound is prepared by the procedure of Example 92 using N-(9-fluorenylmethoxycarbonyl)-L-phenylalanine as the α -aminoacyl component. MS(FAB): m/z 607 (M+H).

¹H NMR (CD₃OH): δ 8.11(d, 1H, J=6.9 Hz, H-8); 7.31(bs, 5H, C₆H₅); 6.92(d, 1H, H-7); 4.40(t, 1H, J=8.9 Hz, CHCO); 4.37(bs, 1H, H-4); 3.53(dd, J=8.25 and 11.40 Hz, H-5); 3.15(d, 2H, J=8.9 Hz, CH₂CHO); 2.92(bs, 6H, NMe₂), 2.70-2.90(m, 2H, H-4a and H-6); 2.51(dd, 1H, J=8.25 and 12.35 Hz, H-5a); and 1.50(d, 3H, J=7.1 Hz, C(6)-CH₃).

5 Example 97

[4S-(4α,12α)]-9-[(L-β-(Cyclohexyl)alanyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- 10 **[0084]** The title compound is prepared by the procedure of Example 92 using N-(9-fluorenylmethoxycarbonyl)-β-cyclohexyl-L-alanine as the α-aminoacyl component.
MS(FAB): m/z 613 (M+H).

Example 98

15

[4S-(4α,12α)]-9-[(L-Leucyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- 20 **[0085]** The title compound is prepared by the procedure of Example 92 using N-(9-fluorenylmethoxycarbonyl)-L-leucine as the α-aminoacyl component.
MS(FAB): m/z 573 (M+H).

Example 99

25

[4S-(4α,12α)]-9-[(L-Glutamyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- 30 **[0086]** The title compound is prepared by the procedure of Example 92 using N-(9-fluorenylmethoxycarbonyl)-L-glutamine as the α-aminoacyl component.
MS(FAB): m/z 588 (M+H).

Example 100

35

[4S-(4α,12α)]-9-[(L-Prolyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- 40 **[0087]** The title compound is prepared by the procedure of Example 90 coupling L-proline with 9-amino-5-hydroxy-6-deoxytetracycline.
MS(FAB): m/z 557 (M+H).

Example 101

45

[4S-(4α,12α)]-9-[(L-(N,N-Dimethylphenylalanyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- [0088]** The title compound is prepared by the procedure of Example 90 coupling L-(N,N-dimethyl)-phenylalanine with 9-amino-5-hydroxy-6-deoxytetracycline.
MS(FAB): m/z 635 (M+H).

50 Example 102

[4S-(4α,12α)]-9-[(L-Tyrosyl)-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

- 55 **[0089]** To a room temperature solution of 4.60 g of N-(9-fluorenylmethoxycarbonyl)-O-(tert-butyl)-L-tyrosine in 50 ml of methylene chloride/tetrahydrofuran (1:1) is added 1.04 g of dicyclohexylcarbodiimide. The reaction mixture is stirred for 1 hour, filtered and concentrated *in vacuo*. The residue is added to a solution of 2.30 g 9-amino-5-hydroxy-6-deoxytetracycline in 30 ml of N-methylpyrrolidone and the mixture is stirred for 4 hours. Five ml of piperidine is added, the

mixture stirred for an additional 30 minutes and concentrated in vacuo. The residue is dissolved in 30 ml of trifluoroacetic acid/anisole (9:1), stirred for 45 minutes and slowly poured into 1000 ml of diethyl ether. The resulting precipitate is collected and purified by reverse phase chromatography to give 1.3 g of the desired product as a gold glass.

MS(FAB): m/z 623 (M+H).

Example 103

[4S-(4alpha,12aalpha)-9-[(L-Lysyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0090] The title compound is prepared by procedure of Example 102 using N α -(9-fluorenylmethoxycarbonyl)-N γ -(tert-butoxycarbonyl)-L-lysine and 9-amino-5-hydroxy-6-deoxytetracycline.

MS(FAB): m/z 588 (M+H).

Example 104


[4S-(4alpha,12aalpha)-9-[(L-Tryptophanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide

[0091] The titled compound is prepared by procedure of Example 102 using N α -(9-fluorenylmethoxycarbonyl)-N-trityl-L-tryptophan and 9-amino-5-hydroxy-6-deoxytetracycline.

MS(FAB): m/z 646 (M+H).

Claims

1. A compound of the formula:



wherein:

R is α -CH₃;


R¹ is selected from hydrogen; straight or branched (C₁-C₄) alkyl group selected from methyl, ethyl, propyl and butyl; straight or branched (C₁-C₄) alkyl group optionally substituted with amino; (heterocyclo)methyl group said heterocycle selected from imidazolyl and 3-indolyl; (C₅-C₆) cycloalkylmethyl group selected from (cyclopentyl)methyl and (cyclohexyl) methyl; (C₂-C₄)carboxamidoalkyl group selected from carboxamidomethyl and carboxamidoethyl;

R² is selected from hydrogen and (C₁-C₂) alkyl selected from methyl and ethyl; W is selected from amino; (C₁-C₈) straight or branched alkyl monosubstituted amino group substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, n-hexyl and n-octyl; (C₃-C₆) cycloalkyl monosubstituted amino group substitution selected from cyclopropyl, cyclopentyl and cyclohexyl,

[(C₄-C₅) cycloalkyl] (C₁-C₄) alkyl monosubstituted amino group substitution selected from (cyclopropyl)methyl and (cyclopropyl)ethyl; (C₃-C₄) alkenyl monosubstituted amino group substitution selected from allyl and 3-butenyl; (C₇-C₁₀) aralkylamino group selected from benzyl, 2-phenylethyl and 1-phenylethyl; straight or branched symmetrical disubstituted (C₂-C₄) alkylamino group substitution selected from dimethyl and diethyl; straight or branched unsymmetrical disubstituted (C₃) alkylamino group substitution selected from methyl (ethyl);(C₂-C₅) azacycloalkyl group selected from pyrrolidiny and piperidiny; 1-azaoxacycloalkyl group selected from morpholiny; substituted 1-azaoxacyclo- alkyl group selected from 2-(C₁-C₃)alkylmorpholiny; [1,n]-

diazacycloalkyl and substituted [1,n]-diazacycloalkyl group selected from piperazinyl, 2-(C₁-C₃)alkyl- piperazinyl, 4-(C₁-C₃)alkylpiperazinyl, and 2,5-diaza-5-methylbicyclo[2.2.1]hept-2-yl and the diastereomers and enantiomers of said [1,n]-diazacycloalkyl and substituted [1,n]-diazacycloalkyl group; 1-azathiacycloalkyl and substituted 1-azathiacycloalkyl group selected from thiomorpholinyl and 2-(C₁-C₃)alkylthiomorpholinyl; N-azolyl group selected from 1-imidazolyl; (heterocycle)methylamino group selected from 2- or 3-thienylmethylamino and 2-, 3- or 4-pyridylmethylamino; (C₁-C₄)alkoxycarbonylamino group substitution selected from methoxycarbonylamino, ethoxycarbonylamino, and 1,1-dimethylethoxycarbonylamino; or R¹ and W taken together are -CH₂CH₂CH₂ NH-; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

2. A compound of the formula:



wherein:

Y is selected from (CH₂)_nX, n = 0-5, X is halogen selected from bromine, chlorine, fluorine and iodine; alternatively, X is a protected amino selected from trifluoroacetylamino, (C₁-C₄) alkoxycarbonylamino [selected from t-butoxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino, allyloxycarbonylamino and 1,1,1-trichloroethoxycarbonylamino], (C₇-C₁₄) arylalkoxycarbonylamino selected from benzyloxycarbonylamino, naphthylmethoxycarbonylamino, 9-fluorenylmethoxycarbonylamino, p-methoxybenzyloxycarbonylamino, and p-nitrobenzyloxycarbonylamino, (C₇-C₂₃) arylalkylamino selected from benzylamine, p-methoxybenzylamine, p-nitrobenzylamine, tritylamine and 4-methoxytritylamine; R, R¹ and R² are as defined in Claim 1.

3. The compound according to Claim 1 wherein said inorganic salts comprise: hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; said organic salts comprise: acetate, benzoate, citrate, cysteine or other amino acid, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate; and said metal complexes comprise: aluminum, calcium, iron, magnesium, manganese and complex salts.

4. ; A compound according to Claim 1,

[4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(dimethylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
[4S-(4alpha, 12aalpha)]-4-(dimethylamino)-9- [[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride;
[4S-(4alpha, 12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl- 1,11-dioxo-9-[[[(dimethylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride;
[7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,6,8,10a, 11-pentahydroxy-5-methyl-10,12-dioxo-2- naphthacenyl]-1-pyrrolidineacetamide;
[7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8, 10a, 11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-1-piperidineacetamide;
[4S-(4alpha,12aalpha)]-9-[[[(butylamino)acetyl]amino]- 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5, 10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
[4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(diethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
[4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl- 1,11-dioxo-9-[[[(1,1-dimethylethylamino)acetyl]amino]- 2-naphthacenecarboxamide;
[7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8, 10a,

11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-1-morpholineacetamide;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide dihydrochloride;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-thienylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-pyridinylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide dihydrochloride;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(methylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,-10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidinecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[[(cyclopropylmethyl)amino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide sulfate;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(dimethylamino)-9-[[[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-5-methyl-2,5-diazabicyclo[2;2;1]heptane-2-acetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-methyl-4-morpholineacetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-2-azabicyclo[2;2;1]heptane-2-acetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-methyl-1-piperazinecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-hydroxy-1-piperazineacetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-10,12-dioxo-2-naphthacenyl]-4-methoxy-a-methyl-1-piperazinecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-(aminomethyl)-alpha-methyl-1-piperidineacetamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[2-methyl-2-(methylamino)-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[2-(dimethylamino)-2-methyl-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[2-(dimethylamino)-3,3-dimethyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[2-(ethylamino)-2-methyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(Aminoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Prolinyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Leucyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Tryptophanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Glutamyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Glutaminyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Lysyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[L-b-(Cyclohexyl)alanyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[L-(N-Methyleucyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.

5. A compound which is one of

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[methoxyamino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[phenylmethoxy]-amino]acetyl]amino]-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-ethyl-1H-pyrazole-1-acetamide;
 [4S-(4alpha,12aalpha)]-9-[[[Cyclobutylmethylamino]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[[2-butenylamino]acetyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[hydroxyamino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[methyl(phenylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-6-methyl-2-azabicyclo[2;2;2]octane-2-acetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-methyl-1-piperazinecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-cyclopropyltetrahydro-4H-thiazine-4-acetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-ethyl-1H-pyrrole-1-acetamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[1H-imidazol-2-ylmethylamino]-acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]alanine;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[[(2-methylcyclopropyl)oxy]-amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[[[(Bicyclo[2;2;2]oct-2-yloxy)amino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[[(3-methyl-2-butenyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[4-[(2-methyl-1-oxopropyl)amino]phenyl]-amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-ethyl-1-pyrrolidineacetamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[[1-methyl-1H-imidazol-2-yl]-methyl]amino]-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[2-(Dicyclopropylamino)-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-tetrahydro-a,2-dimethyl-4H-1,4-thiazine-4-acetamide;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-2-oxo-1-methylethyl]carbamic acid 2-propenyl ester;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[3-(methylsulfonyl)phenyl]-amino]-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[3-methylcyclobutyl]oxy]amino]-1-oxobutyl]-amino]-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[[2-[[1,1-dimethylethyl]-methylamino]-1-oxobutyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-a-ethyl-4-methyl-2-isoxazolidineacetamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-a-ethyl-3-methyl-4H-1,2,4-triazole-4-acetamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-3-hydroxy-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-a-(hydroxymethyl)-4-methyl-1H-imidazole-1-acetamide;
 [4S-(4alpha,12aalpha)]-9-[[2-(Diethylamino)-3-mercapto-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-a-(mercaptomethyl)-1-piperazineacetamide;
 [7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-3-(hexylamino)-4-oxobutanoic acid;
 [7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]tetrahydro-6-(hydroxymethyl)-2H-1,2-isoxazine-2-propanoic acid;
 [7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-3-[ethyl(phenylmethyl)amino]-4-oxobutanoic acid;
 [7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-4-(cyclopropylamino)-5-oxopentanoic acid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-phenylacetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[[4-(Butylamino)(4-hydroxy-phenyl)acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-(4-methoxyphenyl)acetyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(ethylmethylamino)-3-[4-(trifluoromethyl)phenyl]-acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[4-(dimethylamino)phenyl](2-propenylamino)acetyl]-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(D-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Tyrosinyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-(N,N-Dimethylphenylalanyl)amino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(L-Aspartyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.

6. A compound according to Claim 2,


[4S-(4alpha,12aalpha)]-9-[(bromoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide;
 [4S-(4alpha,12aalpha)]-9-[(chloroacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride;
 [4S-(4alpha,12aalpha)]-9-[(bromoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide monohydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(bromoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide monosulfate;

[4S-(4alpha,12aalpha)]-9-[(2-bromo-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-2-methyl-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxobutyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopentyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-2-methyl-1-oxobutyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;


7. A compound which is one of:

[4S-(4alpha,12aalpha)]-9-[(2-Bromo-3-hydroxy-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-3-mercapto-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-3-bromo-4-oxobutanoic acid hydrobromide;
 [7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-4-bromo-5-oxopentanoic acid hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(Bromophenylacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(Bromo(4-hydroxyphenyl)acetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[(Bromo(4-methoxyphenyl)acetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[[Bromo[4-(trifluoromethyl)phenyl]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [4S-(4alpha,12aalpha)]-9-[[Bromo[4-(dimethylamino)phenyl]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrobromide;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester.

8. A method of producing a compound, or its organic and inorganic salt or metal complex, of the formula:




according to Claim 1, which comprises reacting a 9-[(haloacyl)amido]-5-hydroxy-6-(substituted)-6-deoxytetracycline, or its organic and inorganic salt or metal complex, of the formula:




according to Claim 2, with a nucleophile of the formula WH, wherein W is as defined in Claim 1, in a polar-aprotic solvent and in an inert atmosphere.


9. A method of producing a compound, or its organic and inorganic salt or metal complex, of the formula:



according to Claim 2, which comprises reacting 9-amino-5-hydroxy-6-substituted-6-deoxytetracycline, or its organic and inorganic salt or metal complex, of the formula:




with a straight or branched haloacyl halide of the formula:




wherein Y, R, R¹ and R² are as defined in Claim 2 and Q is halogen selected from bromine, chloride, iodine and fluorine, in an inert solvent in a polar-aprotic solvent and in the presence of a base.


10. A method of producing a compound, or its organic and inorganic salt or metal complex, of the formula:



according to Claim 1, which comprises reacting a 9-amino-5-hydroxy-6-substituted-6-deoxytetracycline, or its organic and inorganic salt or metal complex, of the formula:



with an acid chloride of the formula:




wherein R, R¹, R² and W are as defined in Claim 1 and X is halogen selected from bromine, chlorine, iodine and fluorine, in an inert solvent in a polar-aprotic solvent and in the presence of a base.

11. A pharmaceutical composition of matter comprising a pharmacologically effective amount of a compound according to Claim 1 in association with a pharmaceutically acceptable carrier.
12. A compound according to any one of claims 1, 3, 4 or 5 for use as a medicament.
13. Use of a compound according to any one of claims 1, 3, 4 or 5 in the manufacture of a medicament for the treatment of bacterial infections in warm-blooded animals.

Patentansprüche

1. Verbindung der Formel



I,

worin:


R für α -CH₃ steht;

R¹ ausgewählt wird aus Wasserstoff; gerader oder verzweigter (C₁-C₄)-Alkylgruppe, ausgewählt aus Methyl, Ethyl, Propyl und Butyl; gerader oder verzweigter (C₁-C₄)-Alkylgruppe, gegebenenfalls substituiert mit Amino; (Heterocyclo)methylgruppe, besagter Heterocyclus ausgewählt aus Imidazolyl und 3-Indolyl; (C₅-C₆)-Cycloalkylmethylgruppe, ausgewählt aus (Cyclopentyl)methyl und (Cyclohexyl)methyl; (C₂-C₄)-Carboxamidoalkylgruppe, ausgewählt aus Carboxamidomethyl und Carboxamidoethyl;

R² ausgewählt wird aus Wasserstoff und (C₁-C₂)-Alkyl, ausgewählt aus Methyl und Ethyl;

W ausgewählt wird aus Amino; (C₁-C₈) gerader oder verzweigter Alkyl-monosubstituierter Aminogruppe, Substitution ausgewählt aus Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl, n-Hexyl und n-Octyl; (C₃-C₆)-Cycloalkyl monosubstituierter Aminogruppe, Substitution ausgewählt aus Cyclopropyl, Cyclopentyl und Cyclohexyl; [(C₄-C₅)-Cycloalkyl]-(C₁-C₄)-alkyl monosubstituierter Aminogruppe, Substitution ausgewählt aus (Cyclopropyl)methyl und (Cyclopropyl)ethyl; (C₃-C₄)-Alkenyl monosubstituierter Aminogruppe, Substitution ausgewählt aus Allyl und 3-Butenyl; (C₇-C₁₀)-Aralkylaminogruppe, ausgewählt aus Benzyl, 2-Phenylethyl und 1-Phenylethyl; gerader oder verzweigter symmetrisch disubstituierter (C₂-C₄)-Alkylaminogruppe, Substitution ausgewählt aus Dimethyl und Diethyl; gerader oder verzweigter asymmetrisch disubstituierter (C₃)Alkyl-aminogruppe, Substitution ausgewählt aus Methyl(ethyl); (C₂-C₅)-Azacycloalkylgruppe, ausgewählt aus Pyrrolidinyl und Piperidinyl; 1-Azaoxacycloalkylgruppe, ausgewählt aus Morpholinyl; substituierte 1-Azaoxacycloalkylgruppe, ausgewählt aus 2-(C₁-C₃)-Alkylmorpholinyl; [1,n]-Diazacycloalkyl und substituierte [1,n]-Diazacycloalkylgruppe, ausgewählt aus Piperazinyl, 2-(C₁-C₃)-Alkylpiperazinyl, 4-(C₁-C₃)-Alkylpiperazinyl, und 2,5-Diaza-5-methylbicyclo[2.2.1]hept-2-yl und den Diastereomeren und Enantiomeren von besagtem [1,n]-Diazacycloalkyl und substituierte [1,n]-Diazacycloalkylgruppe; 1-Azathiacycloalkyl und substituierte 1-Azathiacycloalkylgruppe, ausgewählt aus Thiomorpholinyl und 2-(C₁-C₃)-Alkylthiomorpholinyl; N-Azolygruppe, ausgewählt aus 1-Imidazolyl; (Heterocyclus)methylaminogruppe, ausgewählt aus 2- oder 3-Thienylmethylamino und 2-, 3- oder 4-Pyridylmethylamino; (C₁-C₄)-Alkoxy-carbonylaminogruppe, Substitution ausgewählt aus Methoxycarbonyl-amino, Ethoxycarbonyl-amino und 1,1-Dimethylethoxycarbonyl-amino; oder R¹ und W zusammengefasst für -CH₂CH₂CH₂NH- stehen; und die pharmakologisch annehmbaren organischen und anorganischen Salze oder Metallkomplexe.

2. Verbindung der Formel:



II,

worin:

Y ausgewählt wird aus $(CH_2)_nX$, $n = 0-5$, X für Halogen steht, ausgewählt aus Brom, Chlor, Fluor und Iod; alternativ X für eine geschützte Aminogruppe steht, ausgewählt aus Trifluoracetylamino, (C_1-C_4) -Alkoxy-carbonylamino, [ausgewählt aus t-Butoxycarbonylamino, Methoxycarbonylamino, Ethoxycarbonylamino, Allyloxycarbonylamino und 1,1,1-Trichlorethoxycarbonylamino], (C_7-C_{14}) -Arylalkoxy-carbonylamino, ausgewählt aus Benzyloxy-carbonylamino, Naphthylmethoxycarbonylamino, 9-Fluorenylmethoxycarbonylamino, p-Methoxybenzyloxycarbonylamino und p-Nitrobenzyloxycarbonylamino, (C_7-C_{23}) -Arylalkylamino [ausgewählt aus Benzylamin, p-Methoxybenzylamin, p-Nitrobenzylamin, Tritylamin und 4-Methoxytritylamin; R, R¹ und R² wie in Anspruch 1 definiert sind.

3. Verbindung gemäß Anspruch 1, wobei besagte anorganische Salze umfassen: Hydrochlorid, Hydrobromid, Hydroiodid, Phosphat, Nitrat oder Sulfat; besagte organische Salze umfassen: Acetat, Benzoat, Citrat, Cystein oder andere Aminosäuren, Fumarat, Glycolat, Maleat, Succinat, Tartrat, Alkylsulfonat oder Arylsulfonat; und besagte Metallkomplexe umfassen: Aluminium, Calcium, Eisen, Magnesium, Mangan und komplexe Salze.
4. Verbindung gemäß Anspruch 1,
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(dimethylamino)acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino) acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monohydrochlorid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(dimethylamino)acetyl]amino]-2-naphthacencarboxamid-dihydrochlorid;
 - [7S(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino) -5,5a,6,6a,7,10,10a,12-octahydro-1,6,8, 10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-1-pyrrolidinacetamid;
 - [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-1-piperidinacetamid;
 - [4S-(4alpha,12aalpha)]-9-[[[(Butylamino)acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(diethylamino)-acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,20,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(1,1-dimethylethylamino)acetyl]amino]-2-naphthacencarboxamid;
 - [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-1-morpholinacetamid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]amino]-2-naphthacencarboxamid-dihydrochlorid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a-6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-thienylmethyl)amino]acetyl]amino]-2-naphthacencarboxamid-dihydrochlorid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid-dihydrochlorid;
 - [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[(2-pyridinylmethyl)amino]acetyl]amino]-2-naphthacencarboxamid-dihydrochlorid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(methylamino)-acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-dihydrochlorid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-2,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidincarboxamid;

[4S-(4alpha,12aalpha)]-9-[[[(Cyclopropylmethyl)amino]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-sulfat;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-dihydrochlorid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monohydrochlorid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[(hexylamino)-acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-dihydrochlorid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-5-methyl-2,5-diazabicyclo-[2.2.1]heptan-2-acetamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-3-methyl-4-morpholinacetamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-2-azabicyclo[2.2.1]heptan-2-acetamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-methyl-1-piperazincarboxamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-hydroxy-1-piperazinacetamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-10,12-dioxo-2-naphthacenyl]-4-methoxy-alpha-methyl-1-piperazincarboxamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-4-(aminomethyl)-alpha-methyl-1-piperidinacetamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-methyl-2-(methylamino)-1-oxopropyl]amino]-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-methyl-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-3,3-dimethyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(ethylamino)-2-methyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,20,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(Aminoacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Prolinyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Leucyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Tryptophanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Glutamyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Glutaminyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Lysyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[[L-beta-(Cyclohexyl)alanyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

dro-3,5,10,12,12apentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-9-[L-(N-Methylleucyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid.

5 5. Verbindung, welche eine ist von:

- [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[methoxyamino]acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[phenylmethoxy]amino]acetyl]amino]-2-naphthacencarboxamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-4-ethyl-1H-pyrazol-1-acetamid;
 [4S-(4alpha,12aalpha)]-9-[[[Cyclobutylmethylamino]-acetyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-9-[[[2-Butenylamino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[hydroxyamino]acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[[methyl(phenylmethyl)amino]acetyl]amino]-2-naphthacencarboxamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-6-methyl-2-aza-bicyclo-[2.2.2]octan-2-acetamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-methyl-1-piperazincarboxamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-cyclopropyltetrahydro-4H-thiazin-4-acetamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-ethyl-1H-pyrrol-1-acetamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[1H-imidazol-2-ylmethylamino]-acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxoethyl]alanin;
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxoethyl]carbaminsäure-1,1-dimethylethylester;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[2-methylcyclopropyl]oxy]amino]acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-9-[[[Bicyclo[2.2.2]oct-2-yloxy]-amino]acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a, 6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[3-methyl-2-butenyl]amino]acetyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a, 6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[4-[(2-methyl-1-oxopropyl)amino]phenyl]-amino]acetyl]-amino]-1,11-dioxo-2-naphthacencarboxamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-3-ethyl-1-pyrrolidinacetamid;
 [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[[2-[[1-methyl-1H-imidazol-2-yl]-methyl]amino]-1-oxopropyl]amino]-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-9-[[2-(Dicyclopropylamino)-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5, 10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]-tetrahydro- α ,2-dimethyl-4H-1,4-thiazin-4-acetamid;
 [7S-(7alpha,10aalpha)]-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxo-1-methylethyl]-carbamini-

säure-2-propenylester;

[4S-(4alpha,22aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[3-(methylsulfonyl)phenyl]-amino]-1-oxopropyl]-amino]-1,11-dioxo-2-naphthacencarboxamid;
[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[2-[[3-methylcyclobutyl]oxy]amino]-1-oxobutyl]-amino]-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;

[4S-(4alpha,12aalpha)]-9-[[2-[(1,1-Dimethylethyl)-methylamino]-1-oxobutyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-penta-hydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-ethyl-4-methyl-2-isoxazolidinacetamid;
[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-ethyl-3-methyl-4H-1,2,4-triazol-4-acetamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-3-hydroxy-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-(hydroxymethyl)-4-methyl-1H-imidazol-1-acetamid;

[4S-(4alpha,12aalpha)]-9-[[2-(Diethylamino)-3-mercapto-1-oxopropyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-alpha-(mercaptomethyl)-1-piperazinacetamid;

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-3-(hexylamino)-4-oxobutansäure;
[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]tetrahydro-6-(hydroxymethyl)-2H-1,2-isoxazin-2-propansäure;

[7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-3-[ethyl(phenylmethyl)-amino]-4-oxobutansäure;

[7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-4-(cyclopropylamino)-5-oxo-pentansäure;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-phenylacetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[[4-(Butylamino)-4-hydroxy-phenyl]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(dimethylamino)-2-(4-methoxyphenyl)acetyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[2-(ethylmethylamino)-3-[4-(trifluormethyl)phenyl]acetyl]amino]-1,4,4a,5,5a,6, 11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9-[[[4-(dimethylamino)phenyl]-(2-propenylamino)acetyl]-amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(D-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Phenylalanyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Tyrosinyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-(N,N-Dimethylphenyl)-alanyl) amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10, 12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;

[4S-(4alpha,12aalpha)]-9-[(L-Aspartyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid.


6. Verbindung gemäß Anspruch 2,

[4S-(4alpha,12aalpha)]-9-[(Bromacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,12,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid;
 [4S-(4alpha,12aalpha)]-9-[(Chloracetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monohydrochlorid;
 [4S-(4alpha,12aalpha)]-9-[(Bromacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monohydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(Bromacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,21,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monosulfat;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-monohydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-2-methyl-1-oxopropyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-1-oxobutyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-4,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-1-oxopentyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-2-methyl-1-oxo-butyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;


7. Verbindung, welche eine ist von:

[4S-(4alpha,12aalpha)]-9-[(2-Brom-3-hydroxy-1-oxopropyl) amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamidhydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(2-Brom-3-mercapto-1-oxopropyl) amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamidhydrobromid;
 [7S-(7alpha,10aalpha)]-4-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-3-brom-4-oxobutansäurehydrobromid;
 [7S-(7alpha,10aalpha)]-5-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-2,6,8,10a,11-pentahydroxy-5-methyl-10,22-dioxo-2-naphthaceny]amino]-4-brom-5-oxopentansäure-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[(Bromphenylacetyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[[Brom(4-hydroxyphenyl)-acetyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamidhydrobromid;
 [4S-(4alpha,12aalpha)]-9-[[Brom(4-methoxyphenyl)acetyl]-amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[[Brom[4-(trifluormethyl)phenyl]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid;
 [4S-(4alpha,12aalpha)]-9-[[Brom[4-(dimethylamino)phenyl]-acetyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamid-hydrobromid; oder
 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthaceny]amino]-2-oxoethyl]-carbaminsäure-1,1-dimethylethylester.

8. Verfahren zum Herstellen einer Verbindung oder ihres organischen und anorganischen Salzes oder Metallkomplexes der Formel:




gemäß Anspruch 1, welches umfasst: Umsetzen eines 9-[(Halogenacyl)amino]-5-hydroxy-6-(substituierten)-6-deoxytetracyclins oder sein organisches und anorganisches Salz oder Metallkomplex der Formel:




gemäß Anspruch 2 mit einem Nucleophil der Formel WH, worin W wie in Anspruch 1 definiert ist, in einem polaren- aprotischen Lösungsmittel und in einer inerten Atmosphäre.


9. Verfahren zum Herstellen einer Verbindung oder ihres organischen und anorganischen Salzes oder Metallkomplexes der Formel:



gemäß Anspruch 2, welches umfasst: Umsetzen von 9-Amino-5-hydroxy-6-substituiertem-6-deoxytetracyclin oder seines organischen und anorganischen Salzes oder Metallkomplexes der Formel:




15 mit einem geraden oder verzweigten Halogenid der Formel




25 worin Y, R, R¹ und R² wie in Anspruch 2 definiert sind und Q für Halogen steht, ausgewählt aus Brom, Chlor, Iod und Fluor, in einem inerten Lösungsmittel in einem polar-aprotischen Lösungsmittel und in Gegenwart einer Base.


- 30 10. Verfahren zum Herstellen einer Verbindung oder ihres organischen und anorganischen Salzes oder Metallkomplexes der Formel:



45 gemäß Anspruch 1, welches umfasst: Umsetzen eines 9-Amino-5-hydroxy-6-substituierten-6-deoxytetracyclins oder seines organischen und anorganischen Salzes oder Metallkomplexes der Formel:



mit einem Säurechlorid der Formel:




worin R, R¹, R² und W wie in Anspruch 1 definiert sind und X ein Halogen darstellt, ausgewählt aus Brom, Chlor, Iod und Fluor, in einem inerten Lösungsmittel in einem polaren-aprotischen Lösungsmittel und in Gegenwart einer Base.

11. Pharmazeutische Zusammensetzung, welche eine pharmakologisch wirksame Menge einer Verbindung gemäß Anspruch 1 in Verbindung mit einem pharmazeutisch annehmbaren Träger umfasst.
12. Verbindung gemäß einem der Ansprüche 1, 3, 4 oder 5 zur Verwendung als Medikament.
13. Verwendung einer Verbindung gemäß einem der Ansprüche 1, 3, 4 oder 5 bei der Herstellung eines Medikaments zum Behandeln von bakteriellen Infektionen in warmblütigen Tieren.

Revendications

1. Composé de formule :



dans lequel :

R est α -CH₃ ;


R¹ est choisi parmi l'hydrogène ; un groupement alkyle en (C₁-C₄) linéaire ou ramifié choisi parmi méthyle, éthyle, propyle et butyle ; un groupement alkyle en (C₁-C₄) linéaire ou ramifié substitué facultativement avec un amino ; un groupement (hétérocyclo)méthyle ledit hétérocycle étant choisi parmi imidazole et 3-indolyne ; un groupement cycloalkyl(en C₅-C₆)méthyle choisi parmi (cyclopentyl)méthyle et (cyclohexyl) méthyle ; un groupement carboxamidoalkyle en (C₂-C₄) choisi parmi carboxamidométhyle et carboxamidoéthyle ;

R² est choisi parmi l'hydrogène et un alkyle en (C₁-C₂) choisi parmi méthyle et éthyle ;

W est choisi parmi amino ; un amino monosubstitué par un alkyle en (C₁-C₈) linéaire ou ramifié, le groupement de substitution étant choisi parmi méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle, n-hexyle et n-octyle ; un amino monosubstitué par un cycloalkyle en (C₃-C₆), le groupement de substitution étant choisi parmi cyclopropyle, cyclopentyle et cyclohexyle ; un amino monosubstitué par un [cycloalkyle en C₄-C₅]-alkyle en (C₁-C₄), le groupement de substitution étant choisi parmi (cyclopropyl)méthyle et (cyclopropyl)éthyle ; un amino monosubstitué par un alcényle en (C₃-C₄), le groupement de substitution étant choisi parmi allyle et 3-butényle ; un groupement aralkyl(en C₇-C₁₀)-amino choisi parmi benzyle, 2-phényléthyle et 1-phényléthyle ; un alkyl(en C₂-C₄)-amino symétriquement disubstitué linéaire ou ramifié, le groupement de substitution étant choisi parmi diméthyle et diéthyle ; un alkyl(en C₃)-amino non symétriquement disubstitué linéaire ou ramifié, le groupement de substitution étant choisi parmi méthyl(éthyle) ; un groupement azacycloalkyle en (C₂-C₅) choisi parmi pyrrolidinyle et pipéridinyle ; un groupement 1-azaoxacycloalkyle choisi parmi morpholinyle ; un groupement 1-azaoxacycloalkyle substitué choisi parmi 2-alkyl(en C₁-C₃)-

morpholinyle ; un groupement [1,n]-diazacycloalkyle et [1,n]-diazacycloalkyle substitué choisi parmi pipérazinyle, 2-alkyl(en C₁-C₃)-pipérazinyle, 4-alkyl (en C₁-C₃)-pipérazinyle, et 2,5-diaza-5-méthylbicyclo[2.2.1]hept-2-yle et les diastéréoisomères et énantiomères dudit groupement [1,n]-diazacycloalkyle et [1,n]-diazacycloalkyle substitué ; un groupement 1-azathiacycloalkyle et 1-azathiacycloalkyle substitué choisi parmi thiomorpholinyle et 2-alkyl(en C₁-C₃)-thiomorpholinyle ; un groupement N-azolyle choisi parmi 1-imidazolyle ; un groupement (hétérocycle)méthylamino choisi parmi 2- ou 3-thiénylméthylamino et 2-, 3- ou 4-pyridylméthylamino ; un groupement alkoxy(en C₁-C₄)-carbonylamino substitué choisi parmi méthoxycarbonylamino, éthoxycarbonylamino, et 1,1-diméthyléthoxycarbonylamino ; ou R¹ et W pris conjointement sont -CH₂CH₂CH₂NH- ; et les sels organiques et inorganiques ou les complexes métalliques pharmacologiquement acceptables.

2. Composé de formule :



dans lequel :

Y est choisi parmi du (CH₂)_nX, n = 0-5, X est un halogène choisi parmi brome, chlore, fluor et iode ; en variante, X est un amino protégé choisi parmi trifluoroacétylamino, alkoxy(en C₁-C₄)-carbonylamino [choisi parmi t-butoxycarbonylamino, méthoxycarbonylamino, éthoxycarbonylamino, allyloxycarbonylamino et 1,1,1-trichloroéthoxycarbonylamino], arylalkoxy(en C₇-C₁₄)-carbonylamino choisi parmi benzyloxycarbonylamino, naphthylméthoxycarbonylamino, 9-fluorénylméthoxycarbonylamino, p-méthoxybenzyloxycarbonylamino, et p-nitrobenzyloxycarbonylamino, arylalkyl(en C₇-C₂₃)-amino [choisi parmi benzylamine, p-méthoxybenzylamine, p-nitrobenzylamine, tritylamine et 4-méthoxytritylamine] ;
R, R¹ et R² sont comme définis dans la revendication 1.

3. Composé selon la revendication 1 dans lequel lesdits sels inorganiques comprennent :

chlorhydrique, bromhydrique, iodhydrique, phosphorique, nitrique ou sulfate ;
lesdits sels organiques comprennent : acétate, benzoate, citrate, cystéine ou autre acide aminé, fumarate, glycolate, maléate, succinate, tartrate, alkylsulfonate ou arylsulfonate ;
et lesdits complexes métalliques comprennent : aluminium, calcium, fer, magnésium, manganèse et sels complexes.

4. Composé selon la revendication 1,

[4S-(4alpha,12alpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[diméthylamino]acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
monochlorhydrate de [4S-(4alpha,12alpha)]-4-(diméthylamino)-9-[[diméthylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
dichlorhydrate de [4S-(4alpha,12alpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[diméthylamino]acétyl]amino]-2-naphthacénecarboxamide ;
[7S-(7alpha,10alpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-1-pyrrolidineacétamide ;
[7S-(7alpha,10alpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-1-pipéridineacétamide ;
[4S-(4alpha,12alpha)]-9-[[butylamino]acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
[4S-(4alpha,12alpha)]-4-(diméthylamino)-9-[[diéthylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;

- [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[1,1-diméthyléthylamino]acétyl]amino]-2-naphthacénecarboxamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-1-morpholineacétamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[phénylméthyl]-amino]acétyl]amino]-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[2-thiényméthyl]-amino]acétyl]amino]-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[2-méthylpropyl]amino]acétyl]-amino]-1,11-dioxo-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[2-pyridinylméthyl]-amino]acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-9-[[[méthylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-α-méthyl-1-pyrrolidinecarboxamide ;
- [4S-(4alpha, 12aalpha)]-9-[[[cyclopropylméthyl]amino]acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- sulfate de [4S-(4alpha,12aalpha)]-9-(diméthylamino)-9-[[[diméthylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-9-[[[diméthylamino]-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- monochlorhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-9-[[[diméthylamino]-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha,12aalpha)]-4-(diméthylamino)-9-[[[diméthylamino]-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[[diméthylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-N-(1-pyrrolidinylméthyl)-2-naphthacénecarboxamide ;
- dichlorhydrate de [4S-(4alpha,12aalpha)]-9-(diméthylamino)-9-[[[hexylamino]acétyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-5-méthyl-2,5-diazabicyclo[2.2.1]heptane-2-acétamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-3-méthyl-4-morpholinacétamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-2-azabicyclo[2.2.1]heptane-2-acétamide ;
- [7S-(7alpha, 10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-4-méthyl-1-pipérazinecarboxamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-4-hydroxy-1-pipérazineacétamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-10,12-dioxo-2-naphthacényl]-4-méthoxy-α-méthyl-1-pipérazinecarboxamide ;
- [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-4-(aminométhyl)-α-méthyl-1-pipérazineacétamide ;
- [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[2-méthyl-2-(méthylamino)-1-oxopropyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(diméthylamino)-2-méthyl-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(diméthylamino)-3,3-diméthyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(éthylamino)-2-méthyl-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha,12aalpha)]-9-[(aminoacétyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
- [4S-(4alpha, 12aalpha)]-9-[(L-prolinyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;

[4S-(4alpha, 12aalpha)]-9-[(L-leucyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[(L-tryptophanyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-glutamyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-glutaminy)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-lysyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-β-(cyclohexyl)alanyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[L-(N-méthylleucyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide.

5. Composé qui est un des :

[4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[méthoxyamino]acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[phénylméthoxy]-amino]acétyl]amino]-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-4-éthyl-1H-pyrazole-1-acétamide ;
 [4S-(4alpha, 12aalpha)]-9-[[[cyclobutylméthylamino]-acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[[[2-buténylamino]acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[hydroxyamino]acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-9-[[[méthyl (phénylméthyl)-amino]acétyl]amino]-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-6-méthyl-2-azabicyclo[2.2.1]octane-2-acétamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-3-méthyl-1-pipérazinecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-3-cyclopropyltétrahydro-4H-thiazine-4-acétamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]-3-éthyl-1H-pyrrole-1-acétamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[1H-imidazol-2-ylméthylamino]-acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha, 10aalpha)]-N-[2-[[9-(aminocarbonyl) -7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,21-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]amino]-2-oxoéthyl]alanine ;
 ester diméthylique de l'acide [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]amino]-2-oxoéthyl] carbamique ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[2-méthylcyclopropyl]oxy]amino]-acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[[[bicyclo[2.2.2]oct-2-yloxy] amino]acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[3-méthyl-2-butényl]amino]acétyl]-amino]-1,11-diaxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-9-[[[4-[(2-méthyl-1-oxopropyl)amino]-phényl]amino]acétyl]amino]-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-

1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle-3-éthyl-1-pyrrolidineacétamide ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-
 6-méthyl-9-[[2-[[[1-méthyl-1H-imidazol-2-yl)méthyl]amino]-1-oxopropyl]amino]-1,11-dioxo-
 2-naphthacénecarboxamide ;
 5 [4S-(4alpha,12aalpha)]-9-[[2-(dicyclopropylamino)-1-oxopropyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,
 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]-tétrahydro- α ,2-diméthyl-4H-1,4-thiazine-
 4-acétamide ;
 10 ester 2-propénylique de l'acide [7S-(7alpha,10aalpha)]-2-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,
 6,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]amino]-2-oxo-
 1-méthyléthyle]-carbamique ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-
 6-méthyl-9-[[2-[[3-(méthylsulfonyl)phényl]amino]-1-oxopropyl]amino]-1,11-dioxo-
 15 2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-
 pentahydroxy-6-méthyl-9-[[2-[[3-(méthylcyclobutyl)oxy]-amino]-1-oxobutyl]amino]-1,11-dioxo-2-naphthacé-
 necarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[[2-[(1,1-diméthyléthyle)méthylamino]-1-oxobutyl]amino]-4-(diméthylamino)-1,4,4a,
 20 5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]- α -éthyl-4-méthyl-
 2-isoxazolidineacétamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 25 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]- α -éthyl-3-méthyl-4H-1,2,4-triazole-
 4-acétamide ;
 [4S-(4alpha,12aalpha)]-4-(diméthylamino)-9-[[2-(diméthylamino)-3-hydroxy-1-oxopropyl]amino]-1,4, 4a, 5,
 5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 30 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]- α -(hydroxyméthyle)-4-méthyl-1H-imidazo-
 le-1-acétamide ;
 [4S-(4alpha, 12aalpha)]-9-[[2-(diméthylamino)-3-mercapto-1-oxopropyl]amino]-4-(diméthylamino)-1,4,4a,
 5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [7S-(7alpha,10aalpha)]-N-[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,7,10,10a,12-octahydro-1,6,8,10a,
 35 11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]- α -(mercaptométhyle)-1-pipérazineacétamide ;
 acide [7S-(7alpha, 10aalpha)]-4-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]amino]-3-(hexylamino)-4-oxobutanoïque ;
 acide [7S-(7alpha,10aalpha)]-4-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 40 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]amino]tétrahydro-6-(hydroxyméthyle)-2H-
 1,2-isoxazine-2-propanoïque ;
 acide [7S-(7alpha,10aalpha)]-4-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]amino]-3-[éthyl(phénylméthyle)amino]-
 4-oxobutanoïque ;
 acide [7S-(7alpha, 10aalpha)]-5-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
 45 1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényle]amino]-4-(cyclopropylamino)-
 5-oxopentanoïque ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(diméthylamino)-2-phénylacétyle]amino]-1,4,4a,5, 5a, 6,11,
 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[[[butylamino] (4-hydroxyphényl)-acétyle]amino]-4-(diméthylamino)-1,4,4a,5,5a,
 50 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(diméthylamino)-2-(4-méthoxyphényl)acétyle]-1,4,4a,5,5a,
 6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[2-(éthylméthylamino)-3-[4-(trifluorométhyle)-phényl]acétyle]ami-
 no]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-
 55 2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-4-(diméthylamino)-9-[[[4-(diméthylamino)phényl](2-propénylamino)acétyle]amino]-
 1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-
 2-naphthacénecarboxamide ;

[4S-(4alpha, 12aalpha)]-9-[(D-phénylalanil)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[(L-phénylalanil)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-tyrosinyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha,12aalpha)]-9-[(L-(N,N-diméthylphénylalanil)-amino)-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 [4S-(4alpha, 12aalpha)]-9-[(L-aspartyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide.

6. Composé selon la revendication 2,

[4S-(4alpha, 12aalpha)]-9-[(bromoacétyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 monochlorhydrate de [4S-(4alpha,12aalpha)]-9-[(chloroacétyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 monobromhydrate de [4S-(4alpha,12aalpha)]-9-[(bromoacétyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 monosulfate de [4S-(4alpha,12aalpha)]-9-[(bromoacétyl)-amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 monobromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-1-oxopropyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-5-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-2-méthyl-1-oxopropyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacène-carboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-1-oxobutyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-1-oxopentyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-2-méthyl-1-oxobutyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacène-carboxamide ;


7. Composé qui est un des :

bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-3-hydroxy-1-oxopropyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacène-carboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(2-bromo-3-mercapto-1-oxopropyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacène-carboxamide ;
 bromhydrate d'acide [7S-(7alpha, 10aalpha)]-4-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]amino]-3-bromo-4-oxobutanoïque ;
 bromhydrate d'acide [7S-(7alpha, 10aalpha)]-5-[[9-(aminocarbonyl)-7-(diméthylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]amino]-4-bromo-5-oxopentanoïque ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(bromophénylacétyl) amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(bromo(4-hydroxyphényl)acétyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha, 12aalpha)]-9-[(bromo(4-méthoxyphényl)acétyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha, 12aalpha)]-9-[(bromo[4-(trifluorométhyl)phényl]acétyl)amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecarboxamide ;
 bromhydrate de [4S-(4alpha,12aalpha)]-9-[(bromo[4-diméthylamino]phényl)acétyl]amino]-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-méthyl-1,11-dioxo-2-naphthacénecar-


boxamide; ou ester 1,1-diméthyléthylque de l'acide

[7S-(7 α ,10 α)]-N-[2-[[9-(aminocarbonyl)-7-(diméthyl-amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-méthyl-10,12-dioxo-2-naphthacényl]amino]-2-oxoéthyl]carbamique.

8. Procédé de production d'un composé, ou de son sel organique et inorganique ou de son complexe métallique, de formule :




selon la revendication 1, qui comprend la réaction d'une 9-[(haloacyl)amido]-5-hydroxy-6-(substitué)-6-désoxytétracycline, ou son sel organique et inorganique ou son complexe métallique, de formule :




selon la revendication 2, avec un nucléophile de formule WH, dans laquelle W est défini comme dans la revendication 1, dans un solvant polaire-apatotique et dans une atmosphère inerte.


9. Procédé de production d'un composé, ou on sel organique et inorganique ou son complexe métallique, de formule :



selon la revendication 2, qui comprend la réaction d'une 9-amino-5-hydroxy-6-substitué-6-désoxytétracycline, ou son sel organique et inorganique ou son complexe métallique, de formule :




avec un halogénure d'haloacyle linéaire ou ramifié de formule :




dans laquelle Y, R, R¹ et R² sont comme définis dans la revendication 2 et Q est un halogène choisi parmi le brome, le chlore, l'iode et le fluor, dans un solvant inerte dans un solvant polaire-aprotique et en présence d'une base.


10. Procédé de production d'un composé, ou son sel organique et inorganique ou son complexe métallique, de formule :



selon la revendication 1, qui comprend la réaction d'une 9-amino-5-hydroxy-6-substitué-6-désoxytétracycline, ou son sel organique et inorganique ou son complexe métallique, de formule :



avec un chlorure d'acide de formule :



dans laquelle R, R¹, R² et W sont comme définis dans la revendication 1 et X est un halogène choisi parmi le brome, le chlore, l'iode et le fluor, dans un solvant inerte dans un solvant polaire-aprotique et en présence d'une base.

11. Composition pharmaceutique de matière comprenant une quantité pharmacologiquement efficace d'un composé selon la revendication 1 en association avec un support pharmaceutiquement acceptable.
12. Composé selon l'une quelconque des revendications 1, 3, 4 ou 5 pour l'utilisation comme médicament.
13. Utilisation d'un composé selon l'une quelconque des revendications 1, 3, 4 ou 5 dans la fabrication d'un médicament pour le traitement des infections bactériennes chez les animaux à sang chaud.